MYndspan announces new study that accurately predicts brain age across the lifespan
Published in Imaging Neuroscience, "Predicting brain age across the adult lifespan" was able to identify and model the arcs of...
Clinical Trial
Caidya Achieves Medidata Rave TSDV Accreditation, Enhancing Clinical Trial Efficiency and Data Integrity
RALEIGH, N.C., June 12, 2024 /PRNewswire/ -- Caidya, a leading provider of clinical trial solutions, is proud to announce its recent...
Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment
This dose escalation study for safety and tolerability of clenbuterol incorporates Springbok's precision muscle MRI analysis and molecular outcome measures...
Positive Data from IceCure’s Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function
ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free...
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar...
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Targeted protein degradation (TPD*) technologies have demonstrated the potential to produce novel treatment approaches Surrozen’s current SWEETS bispecific antibodies are...
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and...
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains...
Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
Science 37 Enrolls 21% of Study Participants at 11x the Speed of Traditional Research Sites Through its Virtual Site and...
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial
Six additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in...
Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data...
Velocity Clinical Research partners with Luminis Health, moves into oncology in the U.S.
Velocity President and Chief Executive, Dr Paul Evans Velocity President and Chief Executive, Dr Paul Evans DURHAM, N.C., June 12,...
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
LEXINGTON, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing treatments for solid...
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with...
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data...
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of...
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy
Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE)...
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and...
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
WINSTON-SALEM, N.C., June 11, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage...